Other News To Note
Wednesday, July 11, 2012
Chelsea Therapeutics International Ltd., of Charlotte, N.C., disclosed plans to reduce head count "significantly," retaining only employees needed to pursue FDA approval of Northera (droxidopa) for symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.